SHYCOCAN

SHYCOCAN® Proprietary Engineering and Technology Platform.

This proprietary platform technology is available across multiple regions which operate within varied regulatory frameworks governing product availability, intended use, and permissible claims. Descriptions of SHYCOCAN® based technologies or systems on this website may reflect region-specific development pathways, regulatory environments, or scientific research contexts. Such information should be interpreted within the appropriate jurisdictional and regulatory setting.

Regulatory & Jurisdictional Notice

Product availability, intended use, claims, and regulatory status vary by country.

Nothing on this website should be construed as a representation that any product is approved, cleared, authorized, or available for use in any specific jurisdiction unless expressly stated.

Regions outside the United States

  • SHYCOCAN®has been referenced in scientific, technical, and research contexts that may include laboratory evaluation, controlled studies, or region-specific development programs.

  • These activities were conducted under local regulatory frameworks, institutional oversight, and jurisdiction-specific requirements applicable at the time and place of study.

Learn more

United States Notice

Labeling, Intended Use, and Regulatory Context

  • In the United States and U.S. territories, SHYCOCAN™ is not marketed, distributed, or offered for sale as a medical or veterinary medical product, and no U.S. medical or veterinary labeling has been established or authorized.

  • Any references to SHYCOCAN® or "‘powered by SHOCOCAN®” are provided solely in a historical, scientific, or platform-development context. Such references do not constitute medical or veterinary product labeling, do not establish a medical intended use, and do not represent promotion of a regulated medical product in the United States.

  • Based on its current intended use and manner of presentation, SHYCOCAN™ is not subject to regulation by the U.S. Food and Drug Administration. In addition, under U.S. regulatory frameworks, registration under the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA) is required only if a product is classified as a pesticide or pesticidal device, and SHYCOCAN® does not meet the definition of a pesticide or pesticidal device per the U.S. Environmental Protection Agency (EPA).

  • No claims—explicit or implied—are made regarding the prevention, treatment, mitigation, or diagnosis of disease in the U.S. market.

Market Update

  • European Union CE Mark as a Class I device

  • Marketing Strategies in place in CE compliant countries

  • Mexico and Latin America marketing and manufacturing strategy in place

Authorized Distributors - North/South America, Mexico, Caribbean

  • Shreis Scalene Therapeutics LLC (MD and VA, USA) - Exclusive marketing, manufacturing, and distribution of the Shreis Scalene SHYCOCAN® (currently not marketed in the US)

    • None of the other US distributors are currently authorized to market the SHYCOCAN® or alternate/renamed versions domestically within the US since November 2023.

  • Envirozyme (San Juan, Puerto Rico): Non-exclusive marketing and distribution of the Shreis Scalene SHYCOCAN®

  • Tres Monos Lab (Mexico City, Mexico): Non-exclusive distribution and product assembly of the Shreis Scalene SHYCOCAN® ( CE Class 1 medical device authorized for sale in Mexico)

  • BLT Inc. (Montreal, Canada): Non-exclusive marketing and distribution of the Shreis Scalene SHYCOCAN® (CE Class 1 medical device, authorized for sale under Health Canada-Class I designation.)

  • Kibovision (Santiago, Chile): Non-exclusive marketing and distribution of the Shreis Scalene SHYCOCAN® (CE Class 1 medical device, authorized for sale in LATAM countries).

  • Other LATAM distributors: Ongoing collaborations - Non-exclusive marketing and distribution of the Shreis Scalene SHYCOCAN®

  • Caribbean Countries: On-going collaborations- Non-exclusive marketing and distribution of the Shreis Scalene SHYCOCAN®

DISCLAIMER: No distributor can make any regulatory development statements on behalf of Shreis Scalene Therapeutics LLC that is not reflected in their agreement. No forward-looking statements are authorized under these agreements. All Distribution/marketing/assembly partners are routinely updated on the marketability of the SHYCOCAN® product in their respective regions. No misleading statements regarding the innovation, the ownership or the regulatory path forward can be claimed by any of the Distribution / Marketing / Product assembly partners. Use of any other name for the Product that has been agreed upon by Shreis, must be clearly labelled as ‘powered by the SHYCOCAN®’ for distribution within the respective territories, under prevailing market compliances.

Shipping Lead Times

SHYCOCAN UNITS WEEKS FOR PRODUCTION AND DELIVERY

1-10 Immediate Order Delivery

10 - 100 Immediate Order Delivery

101 - 1,000 4 - 6 weeks after Purchase

1,001 - 10,000 4 - 6 weeks after Purchase

10,001 - 100,000 30,000 units per month. Shipping by sea will be an additional 30 days

100,000 - 500,000 50,000 units per month and organize multiple centers to fulfill quantity in 4 months.

Shipping by sea will be an additional 30 days

Please note, these are estimated shipping times. Actual shipping times may vary based on production. Contact Shreis with any questions.